Novel urinary protein biomarker panel for early diagnosis of gastric cancer

Shimura, Takaya; Dayde, D.; Wang, Hong; Okuda, Yusuke; Iwasaki, Hiroyasu; Ebi, Masahide; Kitagawa, Mika; Yamada, Tamaki; Yamada, Terumasa; Hanash, Samir M.; Taguchi, Ayumu; Kataoka, Hiromi

doi:10.1038/s41416-020-01063-5

Cited by 49 publications

(33 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no urinary biomarkers have been clinically applied to malignant cases. We have been exploring for urinary biomarkers for a long time and found that urinary protein biomarkers are useful for gastric cancer 15 – 17 and colorectal cancer 18 . Moreover, we recently established a urinary miRNA biomarker panel using miR-6807-5p and miR-6856-5p; this panel can early detect gastric cancer 19 .…”

Section: Introductionmentioning

confidence: 99%

Urinary microRNA biomarkers for detecting the presence of esophageal cancer

Okuda

Shimura

Iwasaki

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Esophageal cancer (EC) including esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) generally exhibits poor prognosis; hence, a noninvasive biomarker enabling early detection is necessary. Age- and sex-matched 150 healthy controls (HCs) and 43 patients with ESCC were randomly divided into two groups: 9 individuals in the discovery cohort for microarray analysis and 184 individuals in the training/test cohort with cross-validation for qRT-PCR analysis. Using 152 urine samples (144 HCs and 8 EACs), we validated the urinary miRNA biomarkers for EAC diagnosis. Among eight miRNAs selected in the discovery cohort, urinary levels of five miRNAs (miR-1273f, miR-619-5p, miR-150-3p, miR-4327, and miR-3135b) were significantly higher in the ESCC group than in the HC group, in the training/test cohort. Consistently, these five urinary miRNAs were significantly different between HC and ESCC in both training and test sets. Especially, urinary miR-1273f and miR-619-5p showed excellent values of area under the curve (AUC) ≥ 0.80 for diagnosing stage I ESCC. Similarly, the EAC group had significantly higher urinary levels of these five miRNAs than the HC group, with AUC values of approximately 0.80. The present study established novel urinary miRNA biomarkers that can early detect ESCC and EAC.

show abstract

Section: Introductionmentioning

confidence: 99%

Urinary microRNA biomarkers for detecting the presence of esophageal cancer

Okuda

Shimura

Iwasaki

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Microfluidic devices have been developed for urinary biomarker marker analysis which can be adapted to create a diagnostic platform for a variety of diseases [ 160 ]. These developments, as well as recent studies identifying candidate urinary protein biomarkers in gastric and prostate cancer, present urine as a promising medium for further proteomic analysis in blood cancers [ 161 , 162 ].…”

Section: Urinementioning

confidence: 99%

Clinical Proteomics of Biofluids in Haematological Malignancies

Dunphy

O’Mahoney

Dowling

et al. 2021

IJMS

View full text Add to dashboard Cite

Since the emergence of high-throughput proteomic techniques and advances in clinical technologies, there has been a steady rise in the number of cancer-associated diagnostic, prognostic, and predictive biomarkers being identified and translated into clinical use. The characterisation of biofluids has become a core objective for many proteomic researchers in order to detect disease-associated protein biomarkers in a minimally invasive manner. The proteomes of biofluids, including serum, saliva, cerebrospinal fluid, and urine, are highly dynamic with protein abundance fluctuating depending on the physiological and/or pathophysiological context. Improvements in mass-spectrometric technologies have facilitated the in-depth characterisation of biofluid proteomes which are now considered hosts of a wide array of clinically relevant biomarkers. Promising efforts are being made in the field of biomarker diagnostics for haematologic malignancies. Several serum and urine-based biomarkers such as free light chains, β-microglobulin, and lactate dehydrogenase are quantified as part of the clinical assessment of haematological malignancies. However, novel, minimally invasive proteomic markers are required to aid diagnosis and prognosis and to monitor therapeutic response and minimal residual disease. This review focuses on biofluids as a promising source of proteomic biomarkers in haematologic malignancies and a key component of future diagnostic, prognostic, and disease-monitoring applications.

show abstract

“…In contrast, there are far fewer studies on urinary biomarkers than on blood-based biomarkers for GI cancers. We and another group previously reported the usefulness of urinary protein and miRNA biomarkers in detecting GI cancers [ 4 , 7 , 8 , 9 , 10 ]. As urine is a completely non-invasive sample, urinary biomarker enables screening tests at home.…”

Section: Diagnostic Biomarkermentioning

confidence: 99%